Organisation paid for research Program year 2025 Source: CMS Open Payments

Bliss Health

Neither a doctor nor a teaching hospital

Research payments

$299,903

39 payments

Through program year 2025, Bliss Health is reported as receiving $299,903 in research payments, across 39 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $110,046 15
2024 Research $169,991 22
2023 Research $2,569 1
2022 Research $17,297 1

Breakdown

Who paid Research payments · program years 2022–2025
  1. AbbVie, Inc. $210,908 23 payments
  2. Gilead Sciences, Inc. $69,130 14 payments
  3. Theratechnologies Inc. $17,297 1 payment
  4. GlaxoSmithKline, LLC. $2,569 1 payment
Studies the money was for Research payments · program years 2022–2025
  1. A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 $163,097 18 payments
  2. A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 $24,188 3 payments
  3. M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 $23,623 2 payments
  4. A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV $19,173 1 payment
  5. Visceral Adiposity Measurement and Observation Study $17,297 1 payment
  6. A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV $10,239 1 payment
  7. A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV $9,100 1 payment
  8. A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV $4,895 1 payment
  9. A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV $4,287 1 payment
  10. A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV $3,468 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record